Cardiovascular Risk and Chronic Obstructive Pulmonary Disease

Who May Qualify: For patients with stable COPD: - Men or women aged 18 to 85 - FEV1/FVC \< 70% or proven BPCO - Patients who have given their free and willing to sign a consent form in writing For patients with decompensated COPD: - Men or women aged 18 to 85 - FEV1/FVC \< 70% or proven BPCO - At the time of acute respiratory failure (ARF), when admitted to hospital: - Respiratory rate \> 25 cycles per minute - PaCO2 \> 45 mmHg - blood pH \< 7.35 - When included in the study: - pH \> 7.33 at the end of ARF, 2 days in a row, or 3 to 7 days post-D1 decompensation (admission to the hospital) - Fever \< 38.5°C - Patients who have given their free and willing to sign a consent form in writing Who Should NOT Join This Trial: - Obvious evolving infection or CRP \> 100 mg/L - Cardiac decompensation considered the main cause of decompensation or chronic heart failure with LVEF \< 45% - Evolving neoplasia - On antioxidants: N-acetyl-cysteine, selenium, vit. C, vit. E - Pregnant or nursing women - Patients under tutorship or curatorship - Patients participating in a drug clinical research study - Patients not affiliated to the French social security system (or equivalent) - Patients deprived of liberty or hospitalized without consent. Always talk to your doctor about whether this trial is right for you.